文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

疑似脓毒性休克24小时未明确诊断:一项实用性多中心前瞻性队列研究

Septic shock with no diagnosis at 24 hours: a pragmatic multicenter prospective cohort study.
PubMed 文献 · Crit Care · 2016-11-06
一句话结论ICU疑似脓毒性休克患者中26%在24小时无感染源或微生物学证据,其中44%最终为脓毒性休克模仿者,且早期确认与未确认者预后无差异。

法国10个ICU前瞻性纳入508例疑似脓毒性休克患者(临床怀疑感染并处方抗生素+需血管活性药的急性循环衰竭)。374例(74%)为早期确认脓毒性休克,134例(26%)24小时无感染源及微生物学证据;后者中37例(28%)为晚期确认,59例(44%)为脓毒性休克模仿者(主要与药物不良反应、急性肠系膜缺血及恶性肿瘤相关),38例(28%)至ICU出院仍原因不明。早期确认组与其余患者在ICU死亡率、ICU住院时长、气管插管时长及血管活性药支持时长上无差异;多变量Cox模型显示第60天死亡风险无差异;符合Sepsis-3标准的亚组(n=369/508)敏感性分析结果一致。

要点

  • 疑似脓毒性休克患者中26%(134/508)在休克发生后24小时无感染源或微生物学证据,其中44%(59/134)最终诊断为脓毒性休克模仿者。
  • 脓毒性休克模仿者主要与药物不良反应、急性肠系膜缺血及恶性肿瘤相关。
  • 早期确认脓毒性休克组与其余患者在ICU死亡率、ICU住院时长、气管插管时长及血管活性药支持时长上无差异。
  • 多变量Cox模型显示早期确认与未确认脓毒性休克患者第60天死亡风险无差异。
  • 符合Sepsis-3标准的亚组(n=369/508)敏感性分析结果与主分析一致。

适用人群与场景

  • 法国10个ICU连续纳入的疑似脓毒性休克成人患者,定义为临床怀疑感染导致抗生素处方,加上需要血管活性药支持的急性循环衰竭。

诊断标准与关键阈值

  • 疑似脓毒性休克:临床怀疑感染导致抗生素处方,加上需要血管活性药支持的急性循环衰竭。
  • 早期确认脓毒性休克:休克发生后24小时内确认感染源或获得微生物学证据。
  • 24小时无诊断:休克发生后24小时无感染源且无微生物学证据。
  • 脓毒性休克模仿者:24小时无诊断但最终诊断为模拟脓毒性休克的非感染性疾病(主要与药物不良反应、急性肠系膜缺血及恶性肿瘤相关)。
  • Sepsis-3定义标准用于敏感性分析亚组(n=369/508)。

研究设计与关键结果

  • 研究类型:实用性、前瞻性、多中心观察性队列研究,法国10个ICU,连续纳入508例疑似脓毒性休克患者。
  • 374例(74%)为早期确认脓毒性休克,134例(26%)24小时无感染源及微生物学证据。
  • 134例中37例(28%)为晚期确认脓毒性休克(24小时后诊断),59例(44%)为脓毒性休克模仿者,38例(28%)至ICU出院仍为不明原因休克。
  • 早期确认组与其余患者在ICU死亡率、ICU住院时长中位数、气管插管时长中位数及血管活性药支持时长中位数上无差异。
  • 多变量Cox模型显示早期确认与未确认脓毒性休克患者第60天死亡风险无差异。
  • 符合Sepsis-3标准的亚组(n=369/508)敏感性分析结果一致。

证据类型、等级与局限

  • 证据类型:前瞻性多中心观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 疑似脓毒性休克患者中约四分之一在24小时无感染源或微生物学证据,其中近半数最终为脓毒性休克模仿者(主要与药物不良反应、急性肠系膜缺血及恶性肿瘤相关),提示对24小时无诊断者需考虑这些模仿情况。
  • 早期确认与未确认脓毒性休克患者的ICU死亡率、ICU住院时长、气管插管时长、血管活性药支持时长及第60天死亡风险均无差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The lack of a patent source of infection after 24 hours of management of shock considered septic is a common and disturbing scenario. We aimed to determine the prevalence and the causes of shock with no diagnosis 24 hours after its onset, and to compare the outcomes of patients with early-confirmed septic shock to those of others.

METHODS: We conducted a pragmatic, prospective, multicenter observational cohort study in ten intensive care units (ICU) in France. We included all consecutive patients admitted to the ICU with suspected septic shock defined by clinical suspicion of infection leading to antibiotic prescription plus acute circulatory failure requiring vasopressor support.

RESULTS: A total of 508 patients were admitted with suspected septic shock. Among them, 374 (74 %) had early-confirmed septic shock, while the 134 others (26 %) had no source of infection identified nor microbiological documentation retrieved 24 hours after shock onset. Among these, 37/134 (28 %) had late-confirmed septic shock diagnosed after 24 hours, 59/134 (44 %) had a condition mimicking septic (septic shock mimicker, mainly related to adverse drug reactions, acute mesenteric ischemia and malignancies) and 38/134 (28 %) had shock of unknown origin by the end of the ICU stay. There were no differences between patients with early-confirmed septic shock and the remainder in ICU mortality and the median duration of ICU stay, of tracheal intubation and of vasopressor support. The multivariable Cox model showed that the risk of day-60 mortality did not differ between patients with or without early-confirmed septic shock. A sensitivity analysis was performed in the subgroup (n = 369/508) of patients meeting the Sepsis-3 definition criteria and displayed consistent results.

CONCLUSIONS: One quarter of the patients admitted in the ICU with suspected septic shock had no infection identified 24 hours after its onset and almost half of them were eventually diagnosed with a septic shock mimicker. Outcome did not differ between patients with early-confirmed septic shock and other patients.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Contou D, Roux D, Jochmans S, et al. Septic shock with no diagnosis at 24 hours: a pragmatic multicenter prospective cohort study. Crit Care. 2016. PMID: 27816060

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。